Your browser doesn't support javascript.
loading
Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy.
Desai, Aakash; Subbiah, Vivek.
Afiliação
  • Desai A; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics (phase 1 clinical trials program), Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cancer ; 129(1): 11-14, 2023 01 01.
Article em En | MEDLINE | ID: mdl-36309827
ABSTRACT
Immunotherapy has changed the landscape of cancer treatment. However, the benefit of immunotherapy is seen only in some cases, with most patients experiencing cancer progression despite treatment with immunotherapy. To overcome this, combination immunotherapy treatments are being studied. Herein, we propose for a precision-driven approach for patient selection to identify successful combinations of immunotherapy to improve outcomes for patients with cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Limite: Humans Idioma: En Revista: Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Limite: Humans Idioma: En Revista: Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos